Glucagon Novo Nordisk (Glucagon)
Emergency treatment for severe hypoglycemia in insulin-treated diabetes
Glucagon Novo Nordisk contains the active substance glucagon and is used for the emergency treatment of severe hypoglycemia (very low blood sugar) in children and adults with insulin-treated diabetes. When a person with diabetes becomes unconscious due to severely low blood sugar and cannot take sugar by mouth, glucagon is administered by injection to rapidly raise blood glucose levels. It is a life-saving medication that should be kept readily available and understood by patients, family members, and caregivers.
Quick Facts
Key Takeaways
- Glucagon Novo Nordisk is an emergency medication for treating severe hypoglycemia (very low blood sugar) when the patient is unconscious or unable to swallow
- It must be reconstituted (mixed with water) immediately before use and injected subcutaneously or intramuscularly — the prepared solution cannot be stored
- Adults receive 1 mg (1 ml); children under 8 years or weighing less than 25 kg receive 0.5 mg (0.5 ml)
- The medication will not work effectively if the patient has depleted liver glycogen stores (e.g., from prolonged fasting, starvation, or heavy alcohol intake)
- Store in a refrigerator (2–8°C) in the original packaging — do not freeze — and always contact a healthcare provider after use
What Is Glucagon Novo Nordisk and What Is It Used For?
Glucagon Novo Nordisk is designed for immediate use in acute hypoglycemic emergencies affecting children and adults with diabetes who use insulin. Severe hypoglycemia occurs when blood glucose drops to dangerously low levels, typically below 3.0 mmol/L (54 mg/dL), causing loss of consciousness, seizures, or inability to eat or drink. In these critical situations, glucagon provides a rapid and effective means of restoring blood sugar levels without requiring intravenous access.
Glucagon is a naturally occurring peptide hormone produced by the alpha cells of the pancreatic islets of Langerhans. It functions as the physiological counterpart to insulin: while insulin lowers blood glucose by promoting cellular uptake, glucagon raises blood glucose by stimulating the liver to convert stored glycogen into glucose through a process called glycogenolysis. The released glucose then enters the bloodstream, increasing blood sugar levels typically within 5 to 15 minutes of injection.
In addition to glycogenolysis, glucagon promotes gluconeogenesis — the synthesis of new glucose from non-carbohydrate precursors such as amino acids and glycerol. This dual mechanism ensures a substantial and sustained rise in blood glucose levels. The medication is manufactured using recombinant DNA technology in yeast, producing human-identical glucagon as the hydrochloride salt.
Beyond its primary emergency indication, glucagon is also used in clinical settings as a diagnostic aid. Healthcare professionals may use it to temporarily relax the smooth muscle of the gastrointestinal tract during endoscopic or radiological examinations of the stomach, duodenum, small intestine, or colon. The doses and routes of administration differ for diagnostic use compared to hypoglycemia treatment.
Make sure your family members, close friends, and colleagues know about Glucagon Novo Nordisk. Show them where you store it and how to use it before an emergency occurs. If you become unconscious, they must act quickly — prolonged unconsciousness from hypoglycemia can be harmful. After receiving glucagon, always contact your healthcare provider to determine the cause of the severe hypoglycemia and how to prevent it from happening again.
What Should You Know Before Using Glucagon Novo Nordisk?
Contraindications
Glucagon Novo Nordisk must not be used in the following situations:
- Allergy to glucagon: If you have a known hypersensitivity to glucagon or any of the other ingredients in this medicine (lactose monohydrate, hydrochloric acid, sodium hydroxide, water for injections), you must not use it. Allergic reactions to glucagon are extremely rare but can include wheezing, sweating, palpitations, rash, facial swelling, and collapse.
- Pheochromocytoma: If you have a tumor of the adrenal gland (pheochromocytoma), glucagon must not be used. Glucagon can stimulate the release of catecholamines from the tumor, potentially causing a dangerous surge in blood pressure and heart rate that could lead to a hypertensive crisis.
Warnings and Precautions
Glucagon Novo Nordisk may not work as intended in several specific clinical scenarios. Understanding these limitations is essential for patients and caregivers to ensure appropriate emergency management. The medication relies on adequate hepatic glycogen stores to exert its blood glucose-raising effect; without sufficient glycogen, the liver cannot release glucose in response to glucagon stimulation.
Glucagon may fail to produce an adequate glycemic response in the following situations:
- Prolonged fasting or starvation: Patients who have not eaten for an extended period may have depleted liver glycogen stores. Without stored glycogen, the liver cannot convert glycogen to glucose, and glucagon will be ineffective. In such cases, intravenous glucose is required.
- Low adrenaline (epinephrine) levels: Adrenal insufficiency or conditions causing low catecholamine levels may reduce the effectiveness of glucagon, as catecholamines play a supportive role in the glycogenolytic response.
- Alcohol-induced hypoglycemia: Excessive alcohol consumption impairs hepatic glucose production and can deplete glycogen stores. Glucagon may be partially or completely ineffective when hypoglycemia is caused by alcohol. This is a particularly important consideration, as alcohol-related hypoglycemia is a common cause of severe episodes.
- Glucagon-secreting tumors (glucagonoma): Paradoxically, patients with glucagon-secreting tumors may not respond appropriately to exogenous glucagon administration.
- Insulin-secreting tumors (insulinoma): Glucagon may initially raise blood glucose in patients with insulinomas, but can subsequently stimulate further insulin release, potentially worsening hypoglycemia.
If the patient does not respond to glucagon within 10 minutes (i.e., does not regain consciousness), emergency medical services must be called immediately, and intravenous glucose should be administered by healthcare professionals. Do not administer a second dose without medical guidance, as the lack of response likely indicates depleted glycogen stores.
Pregnancy and Breastfeeding
Glucagon Novo Nordisk can be used during pregnancy and breastfeeding if you experience severe hypoglycemia. Maintaining adequate maternal blood glucose is essential for the health of both mother and baby. Glucagon is a large peptide molecule that does not cross the placental barrier significantly, and animal studies have not shown evidence of teratogenic effects.
Pregnant women with insulin-treated diabetes are at increased risk of hypoglycemic episodes, particularly during the first trimester when insulin sensitivity changes rapidly. Caregivers and family members of pregnant diabetic patients should be especially well-prepared to administer glucagon in emergencies. Always consult your healthcare provider before taking any medication during pregnancy.
Driving and Using Machines
After experiencing severe hypoglycemia, you should not drive or operate machinery until you have fully recovered. Cognitive function, reaction time, and coordination may remain impaired for some time after the blood glucose level normalizes. You are responsible for assessing whether you are fit to drive or perform work that requires alertness. Discuss with your healthcare provider if you are uncertain.
Sodium Content
Glucagon Novo Nordisk contains less than 1 mmol sodium (23 mg) per maximum dose (2 ml), meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does Glucagon Novo Nordisk Interact with Other Drugs?
Drug interactions with Glucagon Novo Nordisk can be clinically significant and should be understood by both patients and healthcare providers. While glucagon is used in emergency situations where there is often little opportunity to assess concurrent medications, awareness of these interactions helps guide post-treatment management and monitoring.
Drugs That Affect Glucagon's Effectiveness
Certain medications can reduce or modify the blood glucose-raising effect of glucagon:
- Insulin: As the physiological antagonist of glucagon, exogenous insulin directly opposes glucagon's glycogenolytic action. In patients with severe hypoglycemia from insulin overdose, high circulating insulin levels may partially counteract glucagon's effect. This does not mean glucagon should not be used — it remains the appropriate emergency treatment — but it explains why some patients may have a delayed or reduced response.
- Indomethacin: This nonsteroidal anti-inflammatory drug (NSAID) used for joint pain and stiffness may reduce the hyperglycemic (blood sugar-raising) effect of glucagon. The mechanism involves inhibition of prostaglandin synthesis, which plays a role in hepatic glucose metabolism.
Drugs Affected by Glucagon
Glucagon can alter the activity of other medications the patient may be taking:
- Warfarin and other oral anticoagulants: Glucagon can enhance the anticoagulant effect of warfarin, potentially increasing the risk of bleeding. This interaction may become clinically relevant when glucagon is administered in large or repeated doses, particularly in the diagnostic setting. Patients on warfarin who receive glucagon should have their International Normalized Ratio (INR) monitored more closely following treatment.
- Beta-blockers: Glucagon can cause transient increases in both blood pressure and heart rate. In patients taking beta-blockers (used for high blood pressure, irregular heart rhythm, or angina), this cardiovascular effect may be more pronounced because beta-blockers mask the usual compensatory mechanisms. However, this effect is typically short-lived and clinically significant only in patients with underlying cardiovascular disease.
| Interacting Drug | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Insulin | Opposes glucagon's blood sugar-raising action | May reduce or delay response | Monitor response; seek medical help if no improvement in 10 min |
| Indomethacin | May reduce hyperglycemic effect of glucagon | Potentially reduced efficacy | Inform healthcare provider; IV glucose may be needed |
| Warfarin | Glucagon increases anticoagulant effect | Increased bleeding risk | Monitor INR closely after glucagon administration |
| Beta-blockers | Transient increase in blood pressure and heart rate | Short-lived cardiovascular effect | Monitor cardiovascular status in patients with heart disease |
Always inform your healthcare provider about all medications you are currently taking, including over-the-counter medicines, herbal supplements, and vitamins. This information is particularly important for post-emergency follow-up care and for adjusting your diabetes management plan to prevent future episodes of severe hypoglycemia.
What Is the Correct Dosage of Glucagon Novo Nordisk?
Always use Glucagon Novo Nordisk exactly as your doctor has instructed. The medication comes as a powder (compact powder cake) that must be dissolved in the provided solvent immediately before injection. The prepared solution should be clear and free of particles — do not use it if it appears gel-like or if the powder has not fully dissolved.
Adults
Standard Adult Dose
Dose: 1 mg (1 ml of reconstituted solution)
Route: Subcutaneous (under the skin) or intramuscular (into a muscle) injection
Onset: Intramuscular: 5–15 minutes; subcutaneous: slightly longer onset
Duration: Approximately 10–40 minutes depending on route
Children
Pediatric Dose — Children Under 8 Years or Weighing Less Than 25 kg
Dose: 0.5 mg (0.5 ml of reconstituted solution)
Route: Subcutaneous or intramuscular injection
Pediatric Dose — Children Over 8 Years or Weighing More Than 25 kg
Dose: 1 mg (1 ml of reconstituted solution) — same as adult dose
Route: Subcutaneous or intramuscular injection
Step-by-Step Preparation and Injection
Reconstitution and injection should be performed as quickly as possible during a hypoglycemic emergency. The following steps should be practiced in advance so that caregivers are confident in the procedure:
- Remove the caps: Take off both plastic caps from the two vials (the powder vial and the solvent vial).
- Draw up the solvent: Using the provided disposable syringe, draw up all the water (solvent) from the solvent vial.
- Inject the solvent into the powder vial: Insert the needle through the rubber membrane (within the marked circle) on the glucagon powder vial and inject all the water into it.
- Dissolve the powder: Leave the needle in the vial and shake gently until all the glucagon powder has dissolved and a clear solution is obtained. Do not use the solution if it is cloudy or contains particles.
- Draw up the solution: Ensure the rubber plunger is fully depressed. With the needle in the solution, slowly draw back the entire solution into the syringe.
- Remove air bubbles: With the needle pointing upward, tap the syringe with your finger to collect air bubbles at the top, then gently push the plunger to expel the air. Set the correct dose (1 ml for adults, 0.5 ml for children under 8 years or <25 kg).
- Inject the dose: Inject subcutaneously (under the skin) or intramuscularly (into a muscle), typically in the thigh, upper arm, or abdomen.
- Position the patient: Turn the unconscious person on their side (recovery position) to prevent choking.
- Post-injection care: Once the person regains consciousness and can eat, give them something high in sugar (sweets, biscuits, fruit juice) followed by a longer-acting carbohydrate snack to prevent blood sugar from dropping again.
| Patient Group | Dose | Volume | Route |
|---|---|---|---|
| Adults | 1 mg | 1 ml | SC or IM |
| Children >8 yrs or >25 kg | 1 mg | 1 ml | SC or IM |
| Children <8 yrs or <25 kg | 0.5 mg | 0.5 ml | SC or IM |
Overdose
If too much Glucagon Novo Nordisk has been administered, or if a child accidentally ingests the medication, contact a healthcare provider, hospital, or poison control center immediately for risk assessment and advice. Glucagon overdose can cause severe and persistent vomiting. However, specific treatment is usually not required, as the effects of glucagon are self-limiting. Supportive care, including hydration and antiemetic therapy if needed, is typically sufficient.
After receiving Glucagon Novo Nordisk, you or someone else must contact your healthcare provider or emergency services. It is essential to determine why the severe hypoglycemia occurred and to adjust your diabetes management plan to prevent recurrence. Eat high-sugar foods immediately upon regaining consciousness to prevent blood sugar from dropping again.
What Are the Side Effects of Glucagon Novo Nordisk?
Like all medicines, Glucagon Novo Nordisk can cause side effects, although not everybody gets them. The side effects of glucagon are generally mild and transient, resolving within a short time after administration. Many patients experience nausea after receiving glucagon, which is a well-known pharmacological effect of the hormone on the gastrointestinal tract rather than a toxic reaction.
It is important to distinguish between side effects of glucagon itself and the symptoms of the underlying severe hypoglycemia, which can include headache, confusion, tremor, sweating, and fatigue. These symptoms typically improve as blood glucose levels normalize.
Common
May affect up to 1 in 10 people
- Nausea
Uncommon
May affect up to 1 in 100 people
- Vomiting
Rare
May affect up to 1 in 1,000 people
- Abdominal pain
Very Rare
May affect up to 1 in 10,000 people
- Allergic reaction — symptoms may include wheezing, sweating, palpitations, rash, facial swelling, and collapse
Additionally, injection site reactions (such as redness, pain, or swelling at the injection site) have been reported with an unknown frequency. These reactions are generally mild and resolve without treatment.
Contact emergency services immediately if you experience any signs of a severe allergic reaction after receiving glucagon, including: difficulty breathing or wheezing, swelling of the face, lips, tongue, or throat, rapid heartbeat, widespread rash or hives, feeling faint or collapsing. Allergic reactions to glucagon are extremely rare but require urgent treatment.
Side Effects When Used for Diagnostic Purposes
When glucagon is used in higher doses for diagnostic procedures (such as gastrointestinal imaging), additional side effects may occur. These include changes in blood pressure, tachycardia (rapid heart rate), hypoglycemia (low blood sugar occurring after the initial glucose-raising effect wears off), and in rare cases, hypoglycemic coma. Healthcare professionals administering glucagon for diagnostic purposes are trained to monitor for and manage these effects.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is important. It allows ongoing monitoring of the medicine's benefit-risk balance. Patients and healthcare professionals are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority, such as the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom.
How Should You Store Glucagon Novo Nordisk?
Proper storage of Glucagon Novo Nordisk is essential to ensure the medication remains effective when needed in an emergency. Glucagon is a peptide hormone that is sensitive to temperature extremes, light, and physical degradation, making correct storage conditions critical.
Follow these storage guidelines carefully:
- Temperature: Store in a refrigerator at 2–8°C (36–46°F). Keep the product in its original packaging to protect from light.
- Do not freeze: Freezing can damage the product and render it ineffective. If the product has been frozen, do not use it.
- Reconstituted solution: Use the prepared solution immediately after mixing. Do not store reconstituted glucagon for later use. Any unused solution must be discarded.
- Expiry date: Do not use after the expiry date printed on the label (marked "EXP"). The expiry date refers to the last day of the stated month.
- Visual inspection: Do not use the reconstituted solution if it becomes gel-like or if the powder does not dissolve completely. A clear, colorless solution should be obtained upon proper reconstitution.
- Packaging integrity: Do not use the kit if the plastic caps have come loose or are missing when you receive it — return the package to the pharmacy.
- Keep out of reach of children: Store the medication in a safe but accessible location where adults can reach it quickly in an emergency.
- Disposal: Do not dispose of medicines in wastewater or household waste. Ask your pharmacist about proper disposal methods for unused medicines. These measures help protect the environment.
Keep a backup kit available and regularly check the expiry dates on all glucagon kits. Many patients carry one kit at home and another in a travel bag or workplace. Set a reminder on your phone or calendar to check expiry dates every few months, and replace expired kits promptly.
What Does Glucagon Novo Nordisk Contain?
Understanding the composition of Glucagon Novo Nordisk is important for identifying potential allergens and understanding the pharmaceutical formulation. The product consists of two components: a sterile white powder (compact powder cake) in one vial and a solvent in a separate vial.
Active Ingredient
The active substance is glucagon 1 mg as hydrochloride, produced in yeast (Saccharomyces cerevisiae) using recombinant DNA technology. This means the glucagon is bioidentical to human glucagon — it has the same amino acid sequence as the naturally occurring hormone produced by the pancreas. The recombinant production method ensures high purity and consistency between batches.
Inactive Ingredients (Excipients)
- Lactose monohydrate: Used as a bulking agent and stabilizer for the freeze-dried powder. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should be aware of this ingredient, although the amount is very small.
- Water for injections: The solvent used to reconstitute the powder.
- Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment to ensure the solution is within the optimal pH range for injection.
Product Appearance and Packaging
Glucagon Novo Nordisk is supplied as a white, sterile glucagon powder (compact cake) in an injection vial, together with a vial of solvent. The reconstituted solution contains glucagon 1 mg/ml and should be clear and colorless. The product is available in pack sizes of 1 x 1 mg and 10 x 1 mg, although not all pack sizes may be marketed in every country.
The marketing authorization holder and manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark. This medicine is approved within the European Economic Area and the United Kingdom under the names GlucaGen (in most countries) and Glucagon Novo Nordisk (in Norway and Sweden).
What Additional Information Is Available for Healthcare Professionals?
This section provides supplementary clinical information for healthcare professionals managing patients who require glucagon therapy.
Treatment of Severe Hypoglycemia
Glucagon should be administered as a subcutaneous or intramuscular injection. Due to the instability of glucagon in solution, the reconstituted product must be used immediately and must not be administered as an intravenous infusion. If the patient does not respond to treatment within 10 minutes, intravenous glucose should be administered. Once the patient has responded, oral carbohydrates should be given to restore hepatic glycogen stores and prevent relapse of hypoglycemia.
Diagnostic Use
Glucagon is used as an adjunct in endoscopic and radiological examinations of the gastrointestinal tract to reduce motility and facilitate imaging. The dose varies between 0.2–2 mg depending on the examination technique and route of administration:
- Stomach, duodenal bulb, duodenum, and small intestine: 0.2–0.5 mg intravenously or 1 mg intramuscularly
- Colon: 0.5–0.75 mg intravenously or 1–2 mg intramuscularly
After intravenous injection of 0.2–0.5 mg, the onset of action occurs within 1 minute with a duration of 5–20 minutes. After intramuscular injection of 1–2 mg, onset is 5–15 minutes with a duration of approximately 10–40 minutes.
Caution should be exercised when using glucagon as a diagnostic aid in patients with diabetes mellitus or cardiovascular disease. After the diagnostic procedure, oral carbohydrates should be administered (if compatible with the examination protocol). Remember that glucagon has the opposite effect to insulin, and blood glucose monitoring may be necessary.
Frequently Asked Questions About Glucagon Novo Nordisk
Glucagon Novo Nordisk is used as an emergency treatment for severe hypoglycemia (very low blood sugar) in children and adults with insulin-treated diabetes. It is administered when the person is unconscious or unable to take sugar by mouth. The medication contains glucagon, a natural hormone that stimulates the liver to release stored glucose, rapidly raising blood sugar levels within 5 to 15 minutes of injection. It is also used by healthcare professionals as a diagnostic aid to temporarily relax the gastrointestinal tract during medical imaging procedures.
To prepare Glucagon Novo Nordisk: (1) Remove the plastic caps from both vials, (2) Draw up all the water into the syringe, (3) Inject the water into the glucagon powder vial through the rubber membrane, (4) Shake gently until completely dissolved and the solution is clear, (5) Draw the solution back into the syringe while removing air bubbles, (6) Set the correct dose (1 ml for adults; 0.5 ml for children under 8 years or weighing less than 25 kg), (7) Inject subcutaneously or intramuscularly, typically in the thigh. Then turn the person on their side and give sugary food when they regain consciousness.
The most common side effect is nausea, which may affect up to 1 in 10 people. Vomiting is uncommon (up to 1 in 100), and abdominal pain is rare (up to 1 in 1,000). Very rarely (up to 1 in 10,000 people), allergic reactions may occur with symptoms such as wheezing, sweating, palpitations, rash, facial swelling, or collapse. Injection site reactions have also been reported. Most side effects are mild and temporary. If you experience signs of a severe allergic reaction, seek immediate medical attention.
Store Glucagon Novo Nordisk in a refrigerator at 2–8°C (36–46°F) in the original packaging to protect from light. Do not freeze the product. The reconstituted (mixed) solution must be used immediately after preparation and cannot be stored for later use. Always check the expiry date before use and do not use the product if the caps have come loose or if the reconstituted solution appears gel-like or cloudy.
Glucagon Novo Nordisk may not work effectively when the patient's liver glycogen stores are depleted. This can occur in several situations: after prolonged fasting or starvation, when the hypoglycemia is caused by excessive alcohol consumption, in patients with adrenal insufficiency (low adrenaline levels), and in patients with glucagon-secreting or insulin-secreting tumors. If the patient does not respond within 10 minutes of receiving glucagon, intravenous glucose must be administered by medical professionals.
Yes, Glucagon Novo Nordisk can be used during pregnancy and breastfeeding if you experience severe hypoglycemia. Maintaining adequate blood sugar levels is critical for both the mother and baby. Glucagon is a large peptide molecule that does not significantly cross the placental barrier. Pregnant women with insulin-treated diabetes may be at higher risk of hypoglycemic episodes, particularly during the first trimester. It is important that family members and caregivers of pregnant diabetic women know how to administer glucagon. Always consult your healthcare provider about diabetes management during pregnancy.
References
This article is based on the following peer-reviewed sources and official prescribing information:
- European Medicines Agency (EMA). GlucaGen Summary of Product Characteristics. EMA GlucaGen Reference. Accessed December 2025.
- Novo Nordisk A/S. Glucagon Novo Nordisk — Package Leaflet: Information for the User. Last updated January 2023.
- American Diabetes Association (ADA). Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Supplement 1). doi:10.2337/dc25-SINT.
- Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. 3rd edition. American Diabetes Association; 2016.
- Yale JF, Duber B, Engwerda EEC, et al. Faster-acting glucagon for treatment of severe hypoglycemia: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2023;25(6):1456-1468. doi:10.1111/dom.15034.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023. WHO Essential Medicines.
- British National Formulary (BNF). Glucagon. National Institute for Health and Care Excellence (NICE). BNF Glucagon Monograph. Accessed December 2025.
- U.S. Food and Drug Administration (FDA). Glucagon for Injection Prescribing Information. FDA Drug Database. Accessed December 2025.
- International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. The Lancet Diabetes & Endocrinology. 2019;7(5):385-396. doi:10.1016/S2213-8587(18)30315-2.
Medical Editorial Team
This article has been written and reviewed by qualified medical professionals with expertise in endocrinology, diabetology, and emergency medicine.
Medical Content Team
Licensed physicians specializing in endocrinology and internal medicine with clinical experience in diabetes management.
Medical Review Board
Independent panel of board-certified specialists who review all content according to international guidelines (WHO, EMA, FDA, ADA).
Pharmacological Review
Clinical pharmacologists ensuring accuracy of drug information, interactions, dosing, and safety data.
Evidence Standards
All medical claims are supported by Level 1A evidence using the GRADE framework. No commercial funding or pharmaceutical sponsorship.
Evidence Framework: All content follows the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. We reference systematic reviews, meta-analyses, and randomized controlled trials from authoritative sources including the WHO, EMA, FDA, ADA, and peer-reviewed medical journals.